ArticleNutrients2026
The Assessment of Availability, Formulation, Price and Its Risk Factors of Potassium-Enriched Low-Sodium Salt in China: Implications for Population-Level Salt Reduction.
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectivesPotassium-enriched lower-sodium salt substitutes (LSSS) offer consumers a practical way to increase potassium intake and decrease sodium intake, thereby reducing their risk of high blood pressure and cardiovascular disease. This risk reduction, however, depends on whether consumers can access affordable, evidence-based LSSS products. This study investigated the availability, formulation and price of LSSS in China.
methodsA cross-sectional salt survey was conducted across 195 supermarkets in 15 cities from 2023 to 2025 in China.
resultsLSSS availability varied substantially by supermarket size: 90.9% of large (33), 88.9% of middle-sized (45), and only 53.0% of small supermarkets (117) stocked LSSS. Of 1861 total salt products surveyed, 310 were LSSS and 1551 were regular salt. A critical evidence-practice gap exists in product formulation: the mean potassium chloride (KCl) content among unique LSSS products was only 16.6%, with 53.4% of LSSS containing <15% KCl. LSSS products are also consistently more expensive than regular salt. The median LSSS price (11.7 yuan/kg) was significantly higher than regular salt (9.8 yuan/kg,
conclusionsConsumer access to affordable, effective LSSS products can be increased by expanding LSSS availability in small supermarkets, incentivizing higher-KCl formulations, and reducing price barriers to consumer adoption, which could substantially contribute to salt reduction at the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.